Nikolaos Kentepozidis

Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients

Αthanasios Kotsakis, Filippos Koinis, Afroditi Katsarou et al. · Scientific Reports · 2016 · 95 citations · Full text

A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide

Αthanasios Kotsakis, E. Papadimitraki, Eleni‐Kyriaki Vetsika et al. · Lung Cancer · 2014 · 64 citations

Vaccination, Htert Cryptic Peptide, Cancer Immunosurveillance +13

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)

John Souglakos, N. Ziras, Stylianos Kakolyris et al. · British Journal of Cancer · 2012 · 64 citations · Full text

A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group

Emmanouil Kontopodis, Dora Hatzidaki, Ioannis Varthalitis et al. · Journal of Chemotherapy · 2013 · 48 citations

Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project

John Souglakos, Ioannis Boukovinas, Stylianos Kakolyris et al. · Annals of Oncology · 2019 · 46 citations · Full text

High-risk Stage Ii, Oncology, Gastrointestinal Oncology +9